Gilead Sciences
GILD
1,722 hedge funds and large institutions have $76.1B invested in Gilead Sciences in 2024 Q1 according to their latest regulatory filings, with 140 funds opening new positions, 636 increasing their positions, 735 reducing their positions, and 169 closing their positions.
6% more call options, than puts
Call options by funds: $728M | Put options by funds: $684M
2% less ownership
Funds ownership: 85.43% → 83.43% (-2%)
3% less funds holding
Funds holding: 1,776 → 1,722 (-54)
12% less capital invested
Capital invested by funds: $86.3B → $76.1B (-$10.2B)
13% less repeat investments, than reductions
Existing positions increased: 636 | Existing positions reduced: 735
17% less first-time investments, than exits
New positions opened: 140 | Existing positions closed: 169
42% less funds holding in top 10
Funds holding in top 10: 24 → 14 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$378M |
| 2 |
Two Sigma Advisers
New York
|
+$301M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$270M |
| 4 |
Two Sigma Investments
New York
|
+$244M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$224M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.35B |
| 2 |
Parnassus Investments
San Francisco,
California
|
-$809M |
| 3 |
Neuberger Berman Group
New York
|
-$354M |
| 4 |
Goldman Sachs
New York
|
-$342M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$270M |
GILD Hedge Fund Activity: Q1 2024 in Review
1,722 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2024, worth a combined $76.1B — down 12% from $86.3B a quarter earlier.
Sellers outnumbered buyers: 169 funds closed out of GILD and 140 opened new positions — a net loss of 29 holders — while 735 trimmed existing stakes and 636 added.
The largest buyer was Citadel Advisors, adding an estimated $378M. The largest seller was Morgan Stanley, cutting an estimated $1.35B.
- 1,722 institutional investors held Gilead Sciences (GILD) as of Q1 2024, down from 1,776 in Q4 2023.
- Funds reported $76.1B of Gilead Sciences stock for Q1 2024, down 12% quarter-over-quarter.
- 140 funds opened new Gilead Sciences positions in Q1 2024 and 169 closed out, a net change of -29 holders.
- The largest Gilead Sciences buyer in Q1 2024 was Citadel Advisors, an estimated $378M added.
- The largest Gilead Sciences seller in Q1 2024 was Morgan Stanley, an estimated $1.35B sold.
Based on aggregated 13F filings for Q1 2024.